A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
← catalyst calendarNCT06637371 · readout in 234 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
21actual
Sites
21
Countries
Australia, Belgium, Canada +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-16 | actual | When the study began enrolling |
| Primary completion | 2027-04-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-10 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Interventions
- Drug: AMG 691
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
measured Up to approximately 11 months
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed